Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Liver detoxification pathways describe the series of enzymatic processes, primarily occurring in the liver, that convert lipophilic substances—including drugs, xenobiotics, and metabolic byproducts—into more hydrophilic metabolites for excretion. This system is broadly categorized into Phase I (functionalization, mainly via cytochrome P450s) and Phase II (conjugation, such as glucuronidation, sulfation, acetylation, glutathione, and amino acid conjugation), which sequentially process toxicants. Phase I generates intermediate metabolites, some of which can be more reactive and potentially harmful, while Phase II reactions generally further increase hydrophilicity and facilitate excretion via urine or bile. These pathways are regulated by nuclear receptors and are critical for drug metabolism, protection against environmental toxins, and prevention of cellular damage, but can also contribute to disease states if dysregulated or genetically impaired.
Induction or inhibition of Phase I or Phase II enzyme activity Alteration of metabolic rates for co-administered drugs
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Liver detoxification pathways.